Regulation of pancreatic cancer therapy resistance by chemokines

SK Gautam, S Basu, A Aithal, NV Dwivedi… - Seminars in cancer …, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by
high resistance and poor response to chemotherapy. In addition, the poorly immunogenic …

Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma

K Ishido, K Hakamada, N Kimura… - Annals of …, 2021 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is highly malignant. While cancers in other
organs have shown clear improvements in 5‐year survival, the 5‐year survival rate of …

Racial disparity in pathologic response following neoadjuvant chemotherapy in resected pancreatic cancer: a multi-institutional analysis from the Central Pancreatic …

I Ogobuiro, AL Collier, K Khan, I de Castro Silva… - Annals of surgical …, 2023 - Springer
Background Major pathologic response (MPR) following neoadjuvant therapy (NAT) in
pancreatic ductal adenocarcinoma (PDAC) patients undergoing resection is associated with …

Which patients benefit from preoperative biliary drainage in resectable pancreatic cancer?

S Blacker, RP Lahiri, M Phillips, G Pinn… - Expert review of …, 2021 - Taylor & Francis
Recent studies have indicated that preoperative biliary drainage (PBD) should not be
routinely performed in all patients suffering from obstructive jaundice before pancreatic …

Relationship between histopathological therapeutic effect and prognosis in oral cancer patients after preoperative S-1 chemotherapy followed by surgery

M Seki, T Sano, M Ogawa, Y Takayama… - Clinical Oral …, 2023 - Springer
Objectives Preoperative S-1 chemotherapy is administered to prevent tumor proliferation
before surgery in oral squamous cell carcinoma (OSCC). The aim of this study was to …

Serum miRNA profiling for early PDAC diagnosis and prognosis: a retrospective study

A Aita, C Millino, C Sperti, B Pacchioni, M Plebani… - Biomedicines, 2021 - mdpi.com
Background: Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and
short survivals have been described in patients with early-stage tumors. Circulating …

Trends in preoperative chemotherapy utilization for proximal pancreatic cancer: are we making progress?

S Mellado, EA Vega, M Abudalou, OC Kutlu… - Journal of …, 2022 - Elsevier
Background While it has been shown that neoadjuvant chemotherapy (NCT) for pancreatic
cancer (PDAC) undergoing pancreaticoduodenectomy (PD) is critical for optimal oncologic …

Impact of neoadjuvant therapy on survival following margin-positive resection for pancreatic cancer

A Chopra, M Zenati, ME Hogg, HJ Zeh… - Annals of Surgical …, 2021 - Springer
Introduction A positive microscopic margin (R1) following resection of pancreatic ductal
adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced …

Treatment of pancreatic adenocarcinoma in relation to survival in the US Military Health System

YL Eaglehouse, S Darmon, AB Park, CD Shriver… - Cancer …, 2024 - Elsevier
Background Pancreatic cancer has a high case fatality and relatively short survival after
diagnosis. Treatment is paramount to improving survival, but studies on the effects of …

Laparoscopic total pancreatectomy after laparoscopic whipple

O Salirrosas, EA Vega, AM Chirban, H Harandi… - Annals of Surgical …, 2024 - Springer
Background The incidence of a second de novo pancreatic ductal adenocarcinoma (PDAC)
among patients with prior cancer has been reported to be 6%., however, as survival …